Ce6-and Bez235-Based Nanomedicine for Chemo-/Photodynamic Combination Therapy of Tumors

被引:8
作者
Deng, Fu-An [1 ,2 ,3 ]
Liu, Yi-Bin [1 ,2 ,3 ]
Zheng, Rong-Rong [1 ,2 ,3 ]
Kong, Ren-Jiang [4 ]
Zhou, Xiang [4 ]
Wang, Jia-Jia [5 ]
Cheng, Hong [4 ]
Li, Shi-Ying [1 ,2 ,3 ]
机构
[1] Guangzhou Med Univ, Guangdong Prov Key Lab Mol Target & Clin Pharmaco, NMPA, Guangzhou 511436, Peoples R China
[2] Guangzhou Med Univ, State Key Lab Resp Dis, Sch Pharmaceut Sci, Guangzhou 511436, Peoples R China
[3] Guangzhou Med Univ, Affiliated Hosp 5, Guangzhou 511436, Peoples R China
[4] Southern Med Univ, Biomat Res Ctr, Sch Biomed Engn, Guangzhou 510515, Peoples R China
[5] Guangzhou Med Univ, Sch Publ Hlth, Guangzhou 511436, Peoples R China
基金
国家重点研发计划; 中国国家自然科学基金;
关键词
mTOR inhibitor; photodynamic therapy; chemotherapy; self-delivery; nanomedicine; DRUG-DELIVERY SYSTEMS; BREAST-CANCER; MTOR; NVP-BEZ235; PHOTOSENSITIZERS; INHIBITOR; MORTALITY; PATHWAY; PI3K;
D O I
10.1021/acsanm.2c01384
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
As a critical regulator of tumor proliferation, the mTOR pathway could enhance the growth, metabolism, and metastasis of numerous malignant tumors, which would weaken the antitumor effect of photodynamic therapy (PDT). Herein, we conceived a pure-drug-assembled nanomedicine (named CeBez) only comprised of the photosensitizer of chlorine e6 (Ce6) and Bez235 (Bez) for chemo-/photodynamic therapy. Bez, a potent inhibitor of the PI3K/AKT/mTOR pathway targeting both PI3K and mTOR, could specifically downregulate mTOR to achieve chemotherapy. CeBez exhibited excellent dispersibility and a favorable stability in water as a result of firm interactions of hydrophobic and electrostatic forces between Bez and Ce6. Particularly, CeBez was capable of passively targeting the tumor site via enhanced permeability and retention (EPR) effects for effective tumor cell internalization after intravenous administration. Under light irradiation, Ce6-mediated PDT could induce cell apoptosis by causing massive singlet oxygen (O-1(2)) generation. Moreover, Bez could not only downregulate mTOR for chemotherapy but also enhance PDT. This self-assembled nanomedicine provided a synergistic effect by efficient chemotherapy and PDT for malignant tumor treatment.
引用
收藏
页码:9277 / 9285
页数:9
相关论文
共 49 条
[1]   Nanoparticles in the clinic: An update [J].
Anselmo, Aaron C. ;
Mitragotri, Samir .
BIOENGINEERING & TRANSLATIONAL MEDICINE, 2019, 4 (03)
[2]   Tumor-Targeted Nanomedicine for Immunotherapy [J].
Cabral, Horacio ;
Kinoh, Hiroaki ;
Kataoka, Kazunori .
ACCOUNTS OF CHEMICAL RESEARCH, 2020, 53 (12) :2765-2776
[3]   Above and Beyond Cancer Thrapy: Translating Biomaterials into the Clinic [J].
Conde, Joao .
TRENDS IN CANCER, 2020, 6 (09) :730-732
[4]   Drug delivery systems for programmed and on-demand release [J].
Davoodi, Pooya ;
Lee, Lai Yeng ;
Xu, Qingxing ;
Sunil, Vishnu ;
Sun, Yajuan ;
Soh, Siowling ;
Wang, Chi-Hwa .
ADVANCED DRUG DELIVERY REVIEWS, 2018, 132 :104-138
[5]   Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors [J].
Din, Fakhar Ud ;
Aman, Waqar ;
Ullah, Izhar ;
Qureshi, Omer Salman ;
Mustapha, Omer ;
Shafique, Shumaila ;
Zeb, Alam .
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2017, 12 :7291-7309
[6]   NVP-BEZ235/Chlorin-e6 co-loaded nanoparticles ablate breast cancer by biochemical and pnotodynamic synergistic effects [J].
Eltahan, Ahmed Shaker ;
Liu, Lu ;
Okeke, Chukwunweike Ikechukwu ;
Huang, Min ;
Han, Lu ;
Chen, Jing ;
Xue, Xue ;
Bottini, Massimo ;
Guo, Weisheng ;
Liang, Xing-Jie .
NANO RESEARCH, 2018, 11 (09) :4846-4858
[7]   Plasma membrane targeted photodynamic O2 economizer for hypoxic tumor therapy [J].
Fan, Gui-Ling ;
Deng, Fu-An ;
Zhou, Xiang ;
Liu, Ling-Shan ;
Huang, Jia-Qi ;
Zhang, Da-Wei ;
Sun, Yun-Xia ;
Chen, A-Li ;
Cheng, Hong ;
Li, Shi-Ying .
BIOMATERIALS, 2021, 273
[8]   Nanotechnology for Multimodal Synergistic Cancer Therapy [J].
Fan, Wenpei ;
Yung, Bryant ;
Huang, Peng ;
Chen, Xiaoyuan .
CHEMICAL REVIEWS, 2017, 117 (22) :13566-13638
[9]   Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: a population-based study [J].
Fidler, Miranda M. ;
Gupta, Sumit ;
Soerjomataram, Isabelle ;
Ferlay, Jacques ;
Steliarova-Foucher, Eva ;
Bray, Freddie .
LANCET ONCOLOGY, 2017, 18 (12) :1579-1589
[10]  
Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI [10.1001/jamaoncol.2016.5688, 10.1001/jamaoncol.2018.2706]